Dermatology / Nephrology / Ophthalmology / Pulmonology / Rheumatology / Cardiology

Integrating the FDA Mycophenolate Safety Standards to Prevent Adverse Pregnancy Outcomes

CME: 1.0

December 27, 2021
/ Print / Reprints /
| Share More
/ Text Size+

The proposed initative is designed to address the Accreditation Council for Graduate Medical Education, the Interprofessional Collaborative Practice, and the National Academy of Medicine competencies, including delivering patient-centered, team-based care and practicing evidence-based medicine as well as competencies for pharmacists including foundational knowledge and essentials for practice and care, developed by the American Association Colleges of Pharmacy's Centers for the Advance of Pharmacy Education (CAPE) Educational Outcomes.

At the conclusion of this education, participants should be able to:

  • Recognize the pregnancy and fetal risks associated with mycophenolate use in female patients of reproductive potential
  • Provide or facilitate counseling and education to female patients of reproductive potential on the need for pregnancy prevention and planning during mycophenolate treatment
  • Report pregnancies that occur during mycophenolate treatment to the Mycophenolate Pregnancy Registry

Post a comment to this article